

## Announcement

### Report on extraordinary general meeting held in NeuroSearch A/S

An extraordinary general meeting was held today in NeuroSearch A/S.

Mr Thomas Hofman-Bang, President and CEO of NKT Holding A/S, was elected as a new member of the Board of Directors.

The suggested amendment to article 5 of the Articles of Association regarding the Board of Directors' authorisation to increase the company's share capital was adopted by the general meeting with more than two-thirds majority but could not be finally adopted as less than half of the share capital was represented at the general meeting.

An extraordinary general meeting will therefore be held on 21 December 2007 at 10 am where the same amendment to the Articles of Association will be presented for final adoption.

Asger Aamund  
Chairman of the Board

#### Contact persons:

Flemming Pedersen, CEO

#### Phone:

+45 4460 8214 or  
+45 2148 0118

Hanne Leth Hillman, Vice President, Director of Investor  
Relations & Corporate Communications

+45 4460 8212 or  
+45 4017 5103

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial part of the Company's activities are partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with among others Abbott and Astellas. The drug pipeline comprises 11 clinical (Phase I-III) development programmes: ACR16 in Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in partnership with GSK, NS1209 in epilepsy and pain (Phase II), ABT-894 in ADHD (Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar disorder and Parkinson's disease (Phase I) and ABT-107 as well as ABT-560 for the treatment of various CNS diseases – both (Phase I) in collaboration with Abbott as well as NSD-644 (Phase I) in collaboration with GSK. In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.